Debra Armstrong
Overview
Explore the profile of Debra Armstrong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lewis P, Forster A, Magowan M, Armstrong D
Eur J Hosp Pharm
. 2019 Oct;
26(5):253-257.
PMID: 31656611
Objectives: The expansion of out-of-hours pharmacy services results from a drive to improve patient care and promote integration into the wider healthcare team. However, there has been little attempt to...
2.
Cardarelli R, Reese D, Roper K, Cardarelli K, Feltner F, Studts J, et al.
Cancer Epidemiol
. 2016 Nov;
46:1-8.
PMID: 27866066
For low dose CT lung cancer screening to be effective in curbing disease mortality, efforts are needed to overcome barriers to awareness and facilitate uptake of the current evidence-based screening...
3.
Henry R, Ciaraldi T, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S
J Clin Endocrinol Metab
. 2013 Jun;
98(8):3446-53.
PMID: 23733372
Context: Pasireotide (SOM230) is a somatostatin analog with affinity for somatostatin receptor subtypes sst₁₋₃ and sst₅. Clinical trials have demonstrated the efficacy of pasireotide in treating Cushing's disease and acromegaly...
4.
M Kelly K, Phillips C, Jenkins C, Norling G, White C, Jenkins T, et al.
Cancer Control
. 2007 Mar;
14(2):167-75.
PMID: 17387302
Background: Data indicate that in 1997 to 1999, only 44% of Appalachian Kentuckians underwent colorectal cancer screening consistent with guidelines. We investigated the reasons for, barriers to, and follow-up of...
5.
Henry R, Mudaliar S, Chu N, Kim D, Armstrong D, Davis T, et al.
J Clin Pharmacol
. 2003 Oct;
43(11):1228-34.
PMID: 14551177
The objective of this study was to compare the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inhaled insulin delivered by the AERx iDMS in young and elderly patients with type...
6.
Mudaliar S, Mohideen P, Deutsch R, Ciaraldi T, Armstrong D, Kim B, et al.
Diabetes Care
. 2002 Aug;
25(9):1597-602.
PMID: 12196433
Objective: To compare the effects of intravenously administered long-acting insulin analog glargine and regular human insulin on activation and deactivation of endogenous glucose output (EGO) and peripheral glucose uptake. Research...
7.
Chu N, Kong A, Kim D, Armstrong D, Baxi S, Deutsch R, et al.
Diabetes Care
. 2002 Mar;
25(3):542-9.
PMID: 11874944
Objective: Traditional cardiovascular risk factors (CVRF) only partly explain the excessive risk of cardiovascular disease in patients with type 2 diabetes. There is now an increasing appreciation for many novel...